These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 31488557)

  • 1. Synergistic effects of PRIMA-1
    Maslah N; Salomao N; Drevon L; Verger E; Partouche N; Ly P; Aubin P; Naoui N; Schlageter MH; Bally C; Miekoutima E; Rahmé R; Lehmann-Che J; Ades L; Fenaux P; Cassinat B; Giraudier S
    Haematologica; 2020 Jun; 105(6):1539-1551. PubMed ID: 31488557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eprenetapopt Plus Azacitidine in
    Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
    J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To target the untargetable: elucidation of synergy of APR-246 and azacitidine in
    Sallman DA
    Haematologica; 2020 Jun; 105(6):1470-1472. PubMed ID: 32482751
    [No Abstract]   [Full Text] [Related]  

  • 4. Eprenetapopt (APR-246) and Azacitidine in
    Sallman DA; DeZern AE; Garcia-Manero G; Steensma DP; Roboz GJ; Sekeres MA; Cluzeau T; Sweet KL; McLemore A; McGraw KL; Puskas J; Zhang L; Yao J; Mo Q; Nardelli L; Al Ali NH; Padron E; Korbel G; Attar EC; Kantarjian HM; Lancet JE; Fenaux P; List AF; Komrokji RS
    J Clin Oncol; 2021 May; 39(14):1584-1594. PubMed ID: 33449813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
    Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Santini V; Stahl M; Sallman DA
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432650. PubMed ID: 38768424
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
    Maslah N; Diawara Y; Sebert M; Giraudier S; Fenaux P; Cassinat B
    Br J Haematol; 2021 Aug; 194(4):e77-e79. PubMed ID: 34145569
    [No Abstract]   [Full Text] [Related]  

  • 9. Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Cluzeau T; Loschi M; Fenaux P; Komrokji R; Sallman DA
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niclosamide combined to Azacitidine to target TP53-mutated MDS/AML cells.
    Maslah N; Rety S; Bonnamy M; Aguinaga L; Huynh T; Parietti V; Giraudier S; Fenaux P; Cassinat B
    Leukemia; 2024 Jul; 38(7):1630-1633. PubMed ID: 38777834
    [No Abstract]   [Full Text] [Related]  

  • 11. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
    Ali D; Jönsson-Videsäter K; Deneberg S; Bengtzén S; Nahi H; Paul C; Lehmann S
    Eur J Haematol; 2011 Mar; 86(3):206-15. PubMed ID: 21114538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.
    Pereira MP; Herrity E; Kim DDH
    Ann Hematol; 2024 Apr; 103(4):1049-1067. PubMed ID: 37770618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
    Müller-Thomas C; Rudelius M; Rondak IC; Haferlach T; Schanz J; Huberle C; Schmidt B; Blaser R; Kremer M; Peschel C; Germing U; Platzbecker U; Götze K
    Haematologica; 2014 Oct; 99(10):e179-81. PubMed ID: 24972774
    [No Abstract]   [Full Text] [Related]  

  • 14. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for
    Mishra A; Tamari R; DeZern AE; Byrne MT; Gooptu M; Chen YB; Deeg HJ; Sallman D; Gallacher P; Wennborg A; Hickman DK; Attar EC; Fernandez HF
    J Clin Oncol; 2022 Dec; 40(34):3985-3993. PubMed ID: 35816664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
    Kojima K
    Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Problem of TP53-Mutant MDS/AML.
    Sallman DA
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S65-S66. PubMed ID: 32862873
    [No Abstract]   [Full Text] [Related]  

  • 18. Prima-1 and APR-246 in Cancer Therapy.
    Zatloukalová P; Galoczová M; Vojtěšek B
    Klin Onkol; 2018; 31(Suppl 2):71-76. PubMed ID: 31023027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
    Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM
    J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
    Lane AA; Garcia JS; Raulston EG; Garzon JL; Galinsky I; Baxter EW; Leonard R; DeAngelo DJ; Luskin MR; Reilly CR; Stahl M; Stone RM; Vedula RS; Wadleigh MM; Winer ES; Mughal T; Brooks C; Gupta IV; Stevenson KE; Neuberg DS; Ren S; Keating J; Konopleva M; Stein A; Pemmaraju N
    Blood Adv; 2024 Feb; 8(3):591-602. PubMed ID: 38052038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.